Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

This phase II trial tests daratumumab given at a reduced frequency with lenalidomide for maintenance therapy for the cost effective treatment of patients with multiple myeloma post stem cell transplant. Darzalex Faspor (also known as Daratumumab-hyaluronidase) is a combination of two drugs used alone or with other drugs to treat adults with certain types of multiple myeloma or light chain amyloidosis. Daratumumab binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill canc

Trial Details

NCT ID
NCT07485647
Phase
PHASE2
Sponsor
Eden Biltibo
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Daratumumab and Recombinant Human Hyaluronidase
  • Lenalidomide
Locations (sample)
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Signed and dated written informed consent
  • Male or female newly diagnosed multiple myeloma (NDMM) patients 18 to 70 years old on the day of signing informed consent who had ASCT with post-AS…
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Patients with high-risk and international staging system (ISS) stage-III disease in 15% of the intent to treat population. Patients with 1q gain, 1…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →